<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2636">
  <stage>Registered</stage>
  <submitdate>7/01/2010</submitdate>
  <approvaldate>7/01/2010</approvaldate>
  <nctid>NCT01051531</nctid>
  <trial_identification>
    <studytitle>A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia</studytitle>
    <scientifictitle>Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects With Schizophrenia When Switching From Oral Antipsychotics</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>R092670SCH3009</secondaryid>
    <secondaryid>CR016522</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Schizophrenia</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Schizophrenia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Paliperidone palmitate

Experimental: Paliperidone palmitate - 


Treatment: drugs: Paliperidone palmitate
One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Treatment response will be evaluated by findings from the PANSS-a 30-item questionnaire that is administered to the patient by a qualified person (ie, rater) to measure the presence/absence and severity of positive and negative symptoms of schizophrenia</outcome>
      <timepoint>Treatment response will be evaluated at 5 times during the study (Day 1, day 38, day 98, day 188, day 368 and day 548).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The change in personal and social performance (PSP) score and evolution of ratio of mild degree dysfunction, varying degree difficulty, and poor level function based on PSP score after switch to paliperidone palmitate</outcome>
      <timepoint>5 visits (Day 1, day 38, day 188, day 368 and day 548)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The rate of discontinuation, the rate of patients hospitalized, the total number and mean duration of institutionalizations, the overall score in global severity of illness, symptom remission, and medication satisfaction questionnaire findings</outcome>
      <timepoint>9 visits (Day 1, day 8, day 38, day 98, day 188, day 278, day 368, day458 and day 548)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The changes in total PANSS score and PANSS sub-domains/symptom factors</outcome>
      <timepoint>5 visits (Day 1, day 38, day 188, day 368 and day 548).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety measures (laboratories, adverse events, ESRS-A)</outcome>
      <timepoint>Laboratories (Days 1 and 548; Adverse events (Days 1, 8,38,68,98,128,158,188,218,248, 278, 308, 338, 368, 398, 448, 458, 488, 518 and 548) ESRS-A (Days 1, 8, 38, 98, 188, 278, 368, 458 and 548)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of healthcare resource utilization</outcome>
      <timepoint>7 visits (Day -7, Day 98, day 188, day 278, day 368, day 458 and day 548)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Signed informed consent to participate in the study obtained

          -  Signed informed consent to participate in the optional pharmacogenomic component of
             the study obtained (refusal to give consent for the pharmacogenomic component of the
             study does not exclude a patient from participation in the clinical study)

          -  Confirmation of diagnosis of schizophrenia according to the Diagnostic and Statistical
             Manual of Mental Disorders, 4th Edition (DSM-IV) within 5 years prior to screening

          -  Patient is willing and able to fill out self-administered questionnaires during the
             study

          -  confirmation that patient has been given an adequate dose of an appropriate oral
             antipsychotic for an adequate period of time before enrollment, but previous treatment
             is considered unsuccessful due to one or more of the following reasons: lack of
             efficacy, lack of tolerability or safety, lack of compliance and/or other reasons to
             switch to another antipsychotic medication</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  The patient's psychiatric diagnosis is due to the direct pharmacological effects of a
             drug of abuse substance or medication, or is due to a general medical condition (eg,
             clinically notable hypothyroidism)

          -  The patient is treatment resistant in the judgment of the investigator

          -  The patient meets the DSM-IV definition of substance dependence (except for nicotine
             and caffeine) within 6 months prior to entry

          -  The patient has a previously defined hypersensitivity (anaphylaxis-type reaction) to
             risperidone or paliperidone or excipients

          -  The patient has received treatment with a long-acting injectable antipsychotic within
             3 injection cycles prior to baseline, received clozapine within 3 months prior to
             screening, received treatment with other investigational agents within 30 days of the
             screening visit, has participated in more than one investigational drug study in the
             past 12 months, or has planned use of other investigational drugs during the time
             frame of the study

          -  History or current symptoms of tardive dyskinesia, history of neuroleptic malignant
             syndrome, or evidence of clinically significant cardiovascular, renal, hepatic,
             gastrointestinal, neurological, endocrine, metabolic or pulmonary disease in the past
             6 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>546</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Dandenong</hospital>
    <hospital> - Elizabeth Vale</hospital>
    <hospital> - Epping</hospital>
    <hospital> - Frankston</hospital>
    <hospital> - Glenside</hospital>
    <hospital> - Heidelberg</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Prahran</hospital>
    <hospital> - Westmead</hospital>
    <postcode> - Dandenong</postcode>
    <postcode> - Elizabeth Vale</postcode>
    <postcode> - Epping</postcode>
    <postcode> - Frankston</postcode>
    <postcode> - Glenside</postcode>
    <postcode> - Heidelberg</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Prahran</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Nanjing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Xian</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daejeon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gwangju</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-Do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Johor Bahru</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kota Bharu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kota Kinabalu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur N/A</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuching</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Tanjong Rambutan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Terengganu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Pasig National Capitol Region</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Pasig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua County</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Khon Kaen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Songkhla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Ubon Ratchathani</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Johnson &amp; Johnson Pte Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to evaluate the safety, tolerability and treatment response of
      paliperidone palmitate administered as once-monthly injections to patients with
      schizophrenia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01051531</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Johnson &amp; Johnson Pte. Ltd. Clinical Trial</name>
      <address>Johnson &amp; Johnson Pte Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>